The use of oncolytic adenoviruses as cancer gene therapy is limited by their uneven penetration and distribution in tumors. We investigated whether the expression of the cell matrix -degradative protein relaxin by adenovirus could improve adenovirus distribution and penetration in tumors. Methods: We generated relaxin-expressing, replication-incompetent (dl-lacZ-RLX) and -competent (Ad-Δ E1B-RLX) adenoviruses by inserting a relaxin gene into the E3 adenoviral region. Controls were parental adenoviruses (dllacZ and Ad-Δ E1B) and phosphate-buffered saline (PBS) (vehicle). Replication-incompetent viruses, which do not lyse cells, were used to assess transduction effi ciency. Viral spread in tumor spheroids, made by dissecting tumor tissue into homogeneous fragments, was assessed by reporter gene (i.e., lacZ) expression. Tumor growth inhibition was assessed by injecting adenoviruses into xenograft tumors in athymic mice (n = 8 or 9). 
Although the selective replication and spread of oncolytic adenoviruses within cancer cells and tissues has had some success as an anticancer treatment, its promise has been limited because of the uneven penetration and distribution of these viruses in tumor tissues. To date, ONYX-015, an oncolytic adenovirus in which the E1B 55-kDa gene has been deleted, has been administered to more than 300 cancer patients with various tumor types ( 1 , 2 ) but has had only limited success (i.e., local tumor regression rates of 0% -14%). Sauthoff et al. ( 3 ) demonstrated that high levels of adenoviruses persisted in xenograft tumors for at least 8 weeks after intratumoral injection of wild-type adenoviruses, but the viral distribution pattern in the tumor tissue was uneven and patchy. Harrison et al. ( 4 ) detected a high level of viruses in persistent viable tumors up to 100 days after the initial viral injection. Thus, despite long-term viral persistence in tumors, the limited spread of virus to cells throughout the tumor could explain the low response rates observed.
Connective tissue and the extracellular matrix appear to play a role in inhibiting viral spread in tumors. Kuriyama et al. ( 5 ) demonstrated that treatment of human U87, U251, or SF767 glioblastoma multiforme -derived brain tumor xenografts with collagenase, dispase, or trypsin, before the intratumoral injection of adenovirus enhanced virus-mediated gene transduction, and Maillard et al. ( 6 ) reported that elastase pretreatment before delivery of adenoviral vectors into rabbit iliac arteries increased viral transduction effi ciency.
Relaxin is a peptide hormone that is structurally related to insulin and insulin-like growth factors ( 7 ) . Treatment of human lung fi broblasts and bleomycin-induced mouse lung fi brosis (i.e., the common end stage of many pneumopathies) tumors with relaxin decreases the synthesis and secretion of interstitial collagens and increases the expression of matrix metalloproteinase and procollagenase ( 8 ) . Relaxin is a potent inhibitor of collagen expression when collagen is overexpressed, but it does not markedly alter basal levels of collagen expression, in contrast to other collagen-modulatory cytokines, such as interferon gamma ( 9 ) . To further explore the barrier role of the extracellular matrix and connective tissue in inhibiting viral spread and penetration within tumor masses, we determined whether the expression of relaxin by adenoviruses increases their spread in tumor tissues.
M ATERIALS AND M ETHODS

Cell Lines and Cell Culture
The human embryonic kidney cell line 293 that expresses the adenoviral E1 region, the brain cancer cell lines U343 and U87MG, the cervical cancer cell line C33A, the liver cancer cell line Hep3B, and the non -small lung cancer cell line A549 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Murine B16BL6 melanoma cells (a metastatic variant of B16 melanoma cells) were obtained from Dr Y. S. Park (Yonsei University, Wonju, South Korea). All cell lines were cultured in Dulbecco's modifi ed Eagle medium (DMEM; Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco BRL), 2 mM l -glutamine, penicillin (100 IU/mL), and streptomycin (50 μ g/mL), except for Hep3B cells, which were cultured in modifi ed Eagle medium (MEM; Gibco BRL), and B16BL6 cells, which were cultured in MEM supplemented with 5% fetal bovine serum, MEM vitamin solution (1 mM; Gibco BRL, product 11120-052), 100 mM sodium pyruvate, 10 mM of MEM nonessential amino acids solution (10 mM; Gibco BRL, product 11140-050), penicillin (500 IU/mL), and streptomycin (50 μ g/mL). All cell lines were maintained at 37 °C in a humidifi ed atmosphere at 5% CO 2 and 95% air. Escherichia coli was propagated in Luria Bertani medium at 37 °C.
Generation of Relaxin-Expressing Adenoviruses
To generate adenoviruses that express relaxin at the E3 region, we fi rst excised the relaxin gene from the vector pDNR-LIB-RLX (ATCC) with the endonucleases Sal I and Hin dIII and subcloned into the vector pCA14 (Microbix, Ontario, Canada) to generate pCA14-RLX. CMV-relaxin-polA expression cassette was then excised from pCA14-RLX and cloned into the adenovirus E3 shuttle vector pSP72-E3 ( 10) that had been predigested with the endonuclease Bam HI to generate pSP72-E3/CMV-RLX. The newly constructed pSP72-E3/CMV-RLX shuttle vector was then linearized with Pvu I digestion. The replication-incompetent adenoviral vector pdl-lacZ that expresses lacZ (i.e., β -galactosidase) at E1 region of adenovirus and E1B 19-kDa -and E1B 55-kDadeleted replication-competent adenoviral vector pAd-Δ ElB were linearized with Spe I digestion. The linearized pSP72-E3/CMV-RLX shuttle vector was then cotransformed into E. coli BJ5183 with the Spe I-digested pdl-lacZ or pAd-Δ ElB for homologous recombination ( 11 ) to generate pdl-lacZ-RLX and pAd-Δ E1B-RLX adenoviral vector, respectively ( Fig. 1 , A) . E1-deleted replication-incompetent adenovirus (dl-lacZ) and E1B 19-kDaand E1B 55-kDa -deleted replication-competent adenovirus (Ad-Δ ElB) were also prepared as previously described ( 12 ) . All viruses were propagated in 293 cells, and the purifi cation, titration, and quality analysis of all adenoviruses used were performed as previously described ( 13 ) . The number of viral particles was calculated from measurements of optical density at 260 nm, where 1 absorbency unit is equivalent to 10 12 viral particles per milliliter, and infectious titers (plaque-forming units per milliliter) were determined by limiting dilution assay on 293 cells; the plaque-forming unit was calculated from infectious titers as follows: T = 10 1+ d ( S -0.5) , where d and S were the log 10 of the dilution and the sum of ratios, respectively. The viral particle/plaqueforming unit ratios for dl-lacZ, dl-lacZ-RLX, Ad-Δ ElB, and Ad-Δ ElB-RLX were 57 : 1, 70 : 1, 22 : 1, and 43 : 1, respectively.
Enzyme-Linked Immunosorbent Assay for Relaxin Expression
We infected 5 × 10 5 U343 or C33A cells with dl-lacZ, dl-lacZ-RLX, Ad-Δ E1B, or Ad-Δ E1B-RLX at various multiplicities of infection (MOIs) in 25-T culture fl asks. Forty-eight hours later, the supernatant was collected by centrifugation at 15 000 g for 10 minutes at 4 °C, and the level of relaxin protein was assessed by enzyme-linked immunosorbent assay (Endogen, Woburn, MA). Serial dilutions of a purifi ed recombinant human relaxin preparation with a known concentration were used to generate a standard curve.
Animal Studies
Male athymic nu/nu and C57BL/6 mice, weighing approximately 20 g at 6 -8 weeks of age, were obtained from Charles River Japan Inc (Yokohama, Japan). All mice were maintained in a laminar airfl ow cabinet under specifi c pathogen-free conditions. All facilities are approved by the Association of Assessment and Accreditation of Laboratory Animal Care, and all animal experiments were conducted under the institutional guidelines established for the Animal Core Facility at Yonsei University College of Medicine.
Preparation of Tumor Spheroids and the Spreading and Penetration of Relaxin-Expressing Replication-Incompetent Adenovirus dl-lacZ-RLX in Spheroids
Xenografts of U343, U87MG, C33A, or A549 cells were established by subcutaneously injecting 1 × 10 7 cells into the abdomen of 6-to 8-week-old male nude mice (Charles River Japan Inc). When a tumor reached a volume of 150 -200 mm 3 (3 -4 weeks), tumor tissue was surgically excised, blood and necrotic tissue were removed from the tissue, and tumor fragments 1 -2 mm in diameter were dissected with sterile 21-gauge needles. These explants (i.e., 30 -50 explants) were plated individually on 1.45% agarose-coated 48-well plates and cultured in DMEM supplemented with 10% fetal bovine serum. Cultures received fresh medium once every 2 weeks. For our experiments, we used only those explants that became spherical (i.e., spheroids) and that were approximately 2 mm in diameter.
For transduction of tumor spheroids, 100 μ L of culture medium was removed from each tumor spheroid culture dish by aspiration, and 50 μ L of adenovirus dl-lacZ or dl-lacZ-RLX in culture medium (i.e., 1 × 10 8 , 1 × 10 9 , or 1 × 10 10 viral particles) was added. Three days later, β -galactosidase expression in each tumor spheroid was assessed by use of 5-bromo-4-chloro-3-indolyl-β -d -galactopyranoside (Life Technologies, Rockville, MD), as described previously ( 14 ) . Each experiment was carried out three to four times with three replicates in each group, and the results were similar in all experiments. Data from a representative experiment are shown.
Spreading and Penetration of dl-lacZ-RLX In Vivo
To determine the extent of viral spread and tumor penetration, subcutaneous xenografts of U343, U87MG, C33A, Hep3B, and A549 cells were established by injecting 1 × 10 7 cells into the abdo men of 6-to 8-week-old male nude mice (123 mice total). When tumors reached a volume of 100 -200 mm 3 , mice were randomly assigned to receive either dl-lacZ or dl-lacZ-RLX adenovirus from 5 × 10 9 to 5 × 10 10 viral particles per 50 μ L that was intratumorally injected into the tumors three times, every other day. Three days after the last injection of virus, animals were killed by decapitation, and tumors were excised to determine viral distribution by assessing β -galactosidase expression with 5-bromo-4-chloro-3-indolyl-β -d -galactopyranoside ( 15 ) . For better quantitation of β -galactosidase gene activity in tumor tissue, entire tumors were homogenized in lysis buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 , and 0.1% Nonidet P-40, at pH 7.0) with a homogenizer (ART Labo rtecnik, Müllheim, Germany). The supernatant was collected by centrifugation at 15 000 g for 10 minutes at 4 °C. The β -galactosidase activity was measured in the supernatant by use of an enhanced β -galactosidase assay kit (Gene Therapy Systems Inc, San Diego, CA) and then normalized to the total protein content of the extract. The protein content of the extracts was measured with a BCA protein assay kit (Pierce Biotechnology, Rockford, IL). Transduction effi ciency was expressed as total cellular β -galactosidase activity per total protein content of each tumor.
Plaque Development Assay
Monolayers of Hep3B cells were infected with adenoviruses at an MOI of 1 × 10 − 4 in six-well plates. After a 4-hour incubation at 37 °C, the infected cells were overlayed with 4 mL of 0.7% UltraPure agarose (Invitrogen, Carlsbad, CA) in DMEM with 5% fetal bovine serum. After 4 -16 days of incubation, the agarose overlay was removed after soaking with 10% trichoroacetic acid for 30 minutes, and the remaining cells were stained with 0.5% crystal violet in 50% methanol. The number of plaques on any given day was plotted as the percentage of plaques on the fi nal day of the assay.
Terminal Deoxynucleotidyltransferase-Mediated Deoxyuridine Triphosphate Nick End Labeling Assay
Apoptosis was examined by use of the terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. U343, U87MG, C33A, Hep3B, and A549 cells were fi rst plated onto chamber slides at a density of 5 × 10 4 cells per chamber. Twenty-four hours later, cells were infected with dl-lacZ or dl-lacZ-RLX adenovirus at an MOI of 5 -10 or with Ad-Δ E1B or Ad-Δ E1B-RLX adenovirus at an MOI of 0.1 -5 for 48 hours. Apoptotic cells were identifi ed by detecting cleaved deoxyribonucleic acid by use of the in situ ApopTag kit (Chemicon International, Temecula, CA) according to the manufacturer's instructions. The apoptotic cells were visually identifi ed in 10 selected fi elds and photographed at a magnifi cation of ×400. More than 2000 cells were counted to calculate the percentage of TUNEL-positive cells (apoptotic cell ratio). To detect apoptotic cells in vivo, formalin-fi xed tissue sections were prepared and processed as described previously ( 10 ) . Briefl y, tumor sections (8 μ m thick) were treated with proteinase K (20 μ g/mL) for 15 minutes, and then endogenous peroxidase was blocked by treating sections with 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 10 minutes. Sections were then incubated with terminal deoxynucleotidyltransferase buffer for 1 hour at 37 °C and were treated with an anti-digoxignenin antibody conjugate for 30 minutes. Standard avidin -biotin immunohistochemical techniques were used to cleave deoxyribonucleic acid according to the manufacturer's recommendations (Chemicon International). Diaminobenzidine was used as a chromogen, and 0.5% methyl green was used as counterstain.
Flow Cytometry Analysis
Development of apoptosis and cell nuclear damage were determined by dual staining with annexin-V -fl uorescein isothiocyanate and propidium iodide and analyzed by fl ow cytometry. Cells were infected with dl-lacZ or dl-lacZ-RLX adenovirus at an MOI of 20 -50 or with Ad-Δ E1B or Ad-Δ E1B-RLX adenovirus at an MOI of 0.5 -20. As a positive control for the induction of apoptosis, cells were treated with 1 μ M camptothecin. After 2 days of infection or treatment with camptothecin, cells were processed according to manufacturer's instruction in the ApoAlert Annexin V -FITC apoptosis kit (Clontech, Palo Alto, CA). Apoptosis and nuclear cell damage were quantifi ed on a fl uorescenceactivated cell sorter (FACS) (Becton Dickinson, Sunnyvale, CA), and data from 10 000 events were collected for further analysis.
Antitumor Effects of Relaxin-Expressing Adenovirus in Human Xenograft Models
Xenograft tumors were implanted in the abdomens of 5-to 6-week-old male nude mice by subcutaneous injection of 1 × 10 7 U343, U87MG, C33A, Hep3B, or A549 cancer cells in 100 μ L of Hanks' balanced salt solution (Gibco BRL). When tumors reached a volume of 60 -80 mm 3 , mice were randomly assigned to one of three groups to receive PBS, Ad-Δ E1B, or Ad-Δ E1B-RLX (eight or nine mice per group). The fi rst day of treatment was designated as day 1. Adenovirus or PBS was administered intratumorally (for C33A tumors, 1 × 10 10 viral particles per tumor in 50 μ L of PBS, and for U343, U87MG, Hep3B, or A549 tumors, 5 × 10 10 viral particles per tumor in 50 μ L of PBS) on days 1, 3, and 5. Tumor growth delay was assessed by taking measurements every 2 or 3 days. Tumor volume was calculated by the following formula: volume = 0.523 LW 2 , where L is length and W is width. Tumor responses to each treatment were compared by use of the Mann -Whitney test. The percentage of surviving mice was determined by monitoring the death of mice (for U87MG tumors) or tumor growth -related events (tumor size of >1000 mm 3 for A549 xenograft tumors or tumor size of >2000 mm 3 for U343, C33A, and Hep3B xenograft tumors) over a period of 80 days. Various endpoints were used for each tumor type because growth characteristics of each tumor model were different.
Evaluation of Tumor Xenograft by Histology and Immunohistochemistry
Tumor tissue was fi xed in 10% formalin and embedded in paraffi n (Wax-it, Vancouver, Canada), and 3-μ m sections were cut. Representative sections were stained with hematoxylin -eosin or with Masson's trichrome and then examined by light microscopy. We used reagents supplied by DAKO ARK (Dako, Carpinteria, CA) to detect adenovirus antigens, as described previously ( 16 ) . The same paraffi n slides were also used to identify apoptotic cells in tumors according to the instructions in the ApopTag kit for detecting cleaved deoxyribonucleic acids in situ with the TUNEL method.
Murine B16BL6 Spontaneous Lung Metastasis Model
A spontaneous metastasis model was used to examine the effect of increased relaxin gene expression on tumor metastasis. Briefl y, 2 × 10 5 B16BL6 cells per mouse were administered subcutaneously into the right hind footpad of a 6-week-old male C57BL/6 mouse (Charles River Korea, Seoul, Korea). When the tumor reached a volume of approximately 200 mm 3 , mice were randomly assigned to one of three groups to receive PBS, Ad-Δ E1B, or Ad-Δ E1B-RLX (fi ve mice per group). The fi rst day of treatment was designated as day 1, and then 5 × 10 10 viral particles per tumor in 50 μ L of PBS, mixed with Lipofectamin and Plus solution (Gibco BRL) at a 2 (2 μ L) : 6 (6 μ L) ratio or PBS was injected directly into the tumor on days 1, 3, and 5. On day 7, primary tumors were surgically removed by amputating the right hind leg below the knee under mild anesthesia. On day 25 after primary tumor removal, the weight of metastatic tumor lesions in the lungs of the mice was assessed.
Orthotopic Hepatocellular Carcinoma Model in Athymic Mice
To determine the effects of systemic injection of relaxinexpressing, replication-competent adenovirus Ad-Δ E1B-RLX on hepatic tumor growth, 1 × 10 5 Hep1 human hepatoma cells in 50 μ L of Hanks' balanced salt solution were injected directly into the left lobe of the liver of athymic nude mice. Seven days after tumor cell implantation, mice were randomly assigned to receive systemic treatment with PBS (5 mice) or with 2 × 10 10 Ad-Δ E1B (four mice) or Ad-Δ E1B-RLX (six mice) viral particles in 100 μ L of PBS three times every other day by tail-vein injection. At 42 days after the tumor challenge, mice were killed by decapitation, and livers were excised. To determine the tumor burden of the excised livers, tumors were then carefully removed from the liver and weighed for comparison.
Toxicology Studies
Because human adenoviruses replicate only in human cells, toxicology studies with adenoviruses are hampered by the availability of animal models; thus, we assessed toxicity in a nonpermissive host, 8-week-old male C58BL/6 mice. For blood analysis, at 3 days after intravenous (tail vein) or intratumoral administration at a dose of 2 × 10 10 dl-lacZ, dl-lacZ-RLX, Ad-Δ ElB, or Ad-Δ ElB-RLX adenoviral particles, blood samples were obtained by cardiac puncture and assayed for the aspartate aminotransferase (AST), alanine aminotransferase (ALT), and serum levels of T-bilirubin to assess liver function. In addition, liver tissues were fi xed in 10% neutral buffered formalin for 24 hours, and 5-μ m tissue sections were cut and stained with hematoxylin and eosin. Examination for tissue toxicity or damage was carried out by an experienced mouse pathologist who was blinded to this study.
Statistical Analysis
Data were expressed as the mean with its 95% confi dence interval (CI). Statistical comparisons were made with Stat View software (Abacus Concepts, Inc, Berkeley, CA) and the Mann -Whitney test (nonparametric rank sum test). P values of less than .05 were considered statistically signifi cant. All statistical tests were twosided. Survival was assessed with the Kaplan -Meier method, and results were compared with a log-rank test (SPSS software, version 12.0, SPSS Inc, Chicago, IL). Differences in survival were considered statistically signifi cant when P values were less than .05.
R ESULTS Transduction Effi ciency and Viral Spread of Relaxin-Expressing Adenovirus
We fi rst examined the expression of relaxin in cultured C33A and U343 cells after their infection with adenovirus dl-lacZ-RLX or Ad-Δ E1B-RLX. Infection with Ad-Δ E1B-RLX induced higher levels of relaxin expression than transduction with dl-lacZ-RLX at all MOIs examined ( Fig. 1 , B ).
Tumor tissue spheroids were then used to evaluate the transduction effi ciency and tissue penetration of relaxin-expressing adenoviruses. Tumor tissue spheroids provide a useful threedimensional model resembling tumor tissue for assessing viral spread and a convenient means of maintaining primary tumor cells in vitro. Spheroids transduced with dl-lacZ-RLX expressed β -galactosidase more strongly on their peripheral surface than spheroids transduced with dl-lacZ ( In contrast, β -galactosidase expression in spheroids transduced with dl-lacZ-RLX was observed throughout the entire spheroid. Thus, relaxin-expressing adenovirus dllacZ-RLX was transduced and spread to the core of the spheroid more effi ciently than the control vector dl-lacZ.
To determine whether the enhanced transduction effi ciency and viral spread of dl-lacZ-RLX observed in tumor spheroids would lead to an increase in lacZ gene delivery to tumor mass in vivo, we used xenograft tumors in mice. In all xenograft models examined, only a few β -galactopyranoside -positive cells were observed in dl-lacZ -transduced tumors, but cells throughout dllacZ-RLX -transduced tumors strongly expressed β -galactosidase ( Fig. 1 , D and Supplementary Fig. 1 , B [available at: http://jnci cancerspectrum.oxfordjournals.org/jnci/content/vol98/issue20 ]). In particular, intense β -galactosidase expression was observed throughout the U87MG and C33A tumor xenografts transduced with dl-lacZ-RLX, indicating extensive viral spread and penetration in these xenograft models.
To further evaluate β -galactosidase expression in vivo, U343 and A549 xenograft tumors were intratumorally injected one, three, and fi ve times with adenovirus dl-lacZ or dl-lacZ-RLX, and β -galactosidase activity was assessed. Tumors transduced with adenovirus dl-lacZ-RLX contained higher levels of β -galactosidase activity than tumors infected with the control virus dl-lacZ, in both U343 and A549 xenograft models ( Fig. 1 , E) . We also observed higher gene transfer effi ciency in tumors injected with adenovirus fi ve times than in tumors injected one or three times. Thus, relaxin expression appeared to enhance transgene expression and viral spread in solid tumors in vitro and in vivo.
Cytopathic Effect and Plaque Formation of Relaxin-Expressing Adenovirus
To achieve a clinically signifi cant therapeutic outcome, replicating adenoviral vectors must be able to be distributed effi ciently throughout the tumor mass and to overcome the barrier imposed by the extracellular matrix. In an attempt to overcome limited tumor mass penetration by oncolytic adenovirus, we generated an E1B-deleted oncolytic adenovirus (termed Ad-Δ E1B-RLX) that expresses relaxin. We fi rst examined Ad-Δ E1B-RLX in an in vitro cytopathic effect assay to determine the effect of relaxin expression on de novo adenoviral replication. Adenovirus Ad-Δ E1B-RLX elicited a greater cytopathic effect than Ad-Δ E1B, indicating that relaxin expression does not inhibit viral replication (data not shown). 1 . Characterization of relaxin-expressing adenoviruses. A ) Schematic representations of the adenoviral vectors used in this study. All indicated adenoviral vectors were derived from full-length adenovirus genomes cloned and manipulated in Escherichia coli as bacterial plasmids. Replication-incompetent adenovirus that does not express relaxin, dl-lacZ, has the whole E1 region deleted and expresses the reporter gene lacZ ( β -galactosidase protein) under the control of the constitutive cytomegalovirus (CMV) promoter inserted into the E1 region. Replication-competent adenovirus that does not express relaxin, Ad-Δ E1B, contains a normal E1A gene but lacks E1B 19-kDa and E1B 55-kDa genes. The replication-incompetent relaxin-expressing adenovirus dl-lacZ-RLX and the replication-competent relaxin-expressing adenovirus Ad-Δ E1B-RLX carry a relaxin gene driven by the CMV promoter that was inserted into the E3 region. Δ E1 and Δ E3 denote the deletion of E1 and E3 genes, respectively. ITR = inverted terminal repeat; Ψ = packaging signal; pA = polyA sequence; IX = protein IX; and RLX = relaxin. B ) Quantitative enzyme-linked immunosorbent assay results showing relaxin expression mediated by adenoviruses dl-lacZ-RLX and Ad-Δ E1B-RLX at multiplicities of infection (MOIs) between 0 and 500. Relaxin concentration was measured in the culture supernatant 48 hours after adenoviral infection with conventional enzyme-linked immunosorbent assay kits. Data are representative of three independent experiments with each point performed in quadruplicate. Error bars indicate 95% confi dence intervals for quadruplicate data points. C ) Transduction effi ciency and viral spread of relaxin-expressing adenovirus in tumor spheroids. We prepared tumor spheroids from the indicated xenograft tumors in mice. Spheroids were transduced with adenoviruses dl-lacZ, which did not express relaxin ( columns 1 ), or dl-lacZ-RLX, which expressed relaxin ( columns 2 ), at 1 × 10 8 , 1 × 10 9 , and 1 × 10 10 viral particles per 50 μ L. Three days after infection, spheroids were processed to visualize β -galactosidase expression ( blue ) and then sectioned. Viral penetration and transduction effi ciency in the central areas of the spheroids were then assessed by light microscopy. In each panel, columns to the left show whole spheroids (stereoscopic light microscope; original magnifi cation = ×38) and columns to the right show sections through the spheroid midpoint (original magnifi cation = ×40). Scale bars are 400 μ m. D ) Transduction effi ciency and viral spread of relaxin-expressing adenovirus in U343, U87MG, C33A, Hep3B, and A549 xenografts. We established xenografts in nude mice and then injected them intratumorally with dl-lacZ or dl-lacZ-RLX adenovirus (at 5 × 10 9 to 5 × 10 10 viral particles per 50 μ L) three times every other day. Three days after the last injection of adenovirus, tumors were harvested and processed to visualize β -galactosidase expression ( blue ). Scale bars are 400 μ m at ×40 and 100 μ m at ×200 magnifi cations (Original magnifi cations = ×40 and ×200, respectively). E ) Quantitation of the β -galactosidase expression in tumor tissue treated one, three, or fi ve times with adenoviruses at 5 × 10 9 virus particles (v.p.) or at 1 × 10 10 v.p. that do not (dl-lacZ) or do (dl-lacZ-RLX) express relaxin. The transduction effi ciency was expressed as total cellular β -galactosidase activity (in milliunits) per total protein content (in milligrams). Data are the means and 95% confi dence intervals of three independent experiments, with each point performed in triplicate.
To visualize the effect of relaxin expression on the cytopathic ability and viral spread into surrounding cells, we used a plaqueforming assay ( Fig. 2 ) . Adenovirus Ad-Δ E1B, which does not express relaxin, generated plaques 16 days after infection, whereas the relaxin-expressing adenovirus Ad-Δ E1B-RLX generated plaques only 4 days after infection, demonstrating that the expression of relaxin is associated with the induction of early viral release and accelerated cell-to-cell spread of viruses.
Relaxin and Apoptosis
We used a terminal TUNEL assay to determine whether the increased cell killing of a relaxin-expressing adenovirus was mediated by the induction of apoptosis. Ad-Δ E1B-RLX induced a statistically signifi cantly higher percentage of all cells examined to undergo apoptosis than Ad-Δ E1B ( P = .025 for U343, P = .012 for U87MG, P = .036 for C33A, P = .028 for Hep3B, and P = .021 for A549) ( Fig. 3 ) . More specifi cally, there were 69.7% (95% CI = 65.0 to 74.4), 77.0% (95% CI = 61.2 to 92.8), 79.8% (95% CI = 61.8 to 97.8), 69.7% (95% CI = 56.0 to 83.4), and 75.2% (95% CI = 74.1 to 76.3) of TUNEL-positive cells among Ad-Δ E1B-RLX -treated U343, U87MG, C33A, Hep3B, and A549 cells, respectively, whereas there were only 32.5% (95% CI = 21.5 to 43.5), 16.5% (95% CI = 11.9 to 21.1), 45.2% (95% CI = 38.5 to 51.9), 38.5% (95% CI = 36.2 to 40.8), and 34.8% (95% CI = 24.9 to 44.7), respectively, of TUNEL-positive, Ad-Δ E1B -treated cells.
The induction of apoptosis by relaxin-expressing adenoviruses was also evaluated with fl ow cytometry in several cell lines ( Table 1 ). Healthy cells are negative for annexin-V and propidium iodide, whereas early apoptotic cells are positive for annexin-V and negative for propidium iodide. When U343 cells were evaluated, 32.15 % (95% CI = 25.7 to 38.6) of cells were apoptotic after treatment with camptothecin, 32.70% (95% CI = 25.2 to 40.2) of cells were apoptotic after infection with the relaxin-expressing adenovirus Ad-Δ E1B-RLX, but only 24.15% (95% CI = 18.1 to 30.2) of cells were apoptotic after infection with Ad-Δ E1B, which does not express relaxin. These same patterns were observed in the rest of the cancer cell lines (U87MG, C33A, Hep3B, and A549) evaluated. Thus, relaxin expressed from adenoviruses was associated with increased levels of apoptosis and is consistent with the results of the cytopathic effect and plaque development assays. To further confi rm the role of relaxin as an apoptosis inducer, we also performed TUNEL and fl ow cytometry analyses with the relaxin-expressing, replication-incompetent adenovirus dl-lacZ-RLX. Two days after adenovirus transduction, the mean percentage of TUNEL-positive apoptotic cells increased by 2.7% (95% CI = 0% to 5.8%) in untreated cultures, by 16.0% (95% CI = 5.7% to 31.7%) in dl-lacZ -transduced cultures, and by 48.6% (95% CI = 38.1% to 66.4%) in dl-lacZ-RLX -transduced cultures ( Table 1 ) . In fl ow cytometry analyses, the percentage of cells in early apoptosis (i.e., cells positive for annexin-V and negative for propidium iodide) was also higher when cells were transduced with dl-lacZ-RLX than with dl-lacZ ( Table 1 ). In another series of experiments, in which A549 or U343 cells were transfected with expression plasmids that did (pSP72 Δ E3-RLX) or did not (pSP72 Δ E3) express relaxin, instead of with adenoviruses, we found that expression of relaxin statistically signifi cantly increased the percentage of cells in the sub-G 1 population, which refl ects the population of apoptotic cells ( Supplementary Fig. 2 , available at: http://jncicancerspectrum.oxfordjournals.org/jnci/ content/vol98/issue20 ). These data demonstrate, for the fi rst time to our knowledge, that the expression of relaxin by adenoviruses could induce apoptosis.
Enhanced Antitumor Effect of Relaxin-Expressing Oncolytic Adenovirus
The relaxin-expressing oncolytic adenovirus Ad-Δ E1B-RLX was next examined for its ability to suppress the growth of human xenograft tumors when administered intratumorally. The growth of all xenograft tumors treated with relaxin-expressing adenovirus Ad-Δ E1B-RLX was substantially delayed compared with that of tumors treated with PBS or with Ad-Δ E1B, which does not express relaxin ( Fig. 4 , A) . For example, by day 32 after treatment, tumors of C33A tumor-bearing mice treated with PBS reached an average tumor volume of 2252 mm 3 (95% CI = 1980 to 2524 mm 3 ), those treated with Ad-Δ E1B reached 917 mm 3 (difference = 1335 mm 3 , 95% CI = 725 to 2449 mm 3 ; P = .007), and those treated with Ad-Δ E1B-RLX reached 77 mm 3 (difference = 2175 mm 3 , 95% CI = 1184 to 3159 mm 3 ; P <.001). In addition, at day 45 after treatment, complete tumor regression was observed in 25% of the mice with Ad-Δ E1B -treated tumors and in 50% of those with Ad-Δ E1B-RLX -treated tumors. The tumor growth suppression that was observed in the C33A xenograft tumor model was also observed in all other xenograft (U343, U87MG, Hep3B, and A549) models tested. We also performed survival analyses for PBS-, Ad-Δ E1B -, and Ad-Δ E1B-RLX -treated tumor-bearing mice ( Fig. 4 , B) . For C33A tumor-bearing mice, 80 days after the beginning of the treatment, 100% (95% CI of survival probability = 63.1% to 100%) of the animals treated with Ad-Δ E1B-RLX were still viable, whereas only 50% (95% CI of survival probability = 15.7% to 84.3%) of Ad-Δ E1B -treated mice were viable. In all xenograft models examined, tumor-bearing mice treated with Ad-Δ E1B-RLX survived longer than those treated with Ad-Δ E1B.
In Vivo TUNEL, Histologic, and Immunohistochemical Characterization
The antitumor activity of intratumorally administered relaxin-expressing oncolytic adenovirus was further investigated by histologic examination. Tumors were harvested from mice in each treatment group 7 days after the third of three sequential (every other day) adenovirus treatments. Most of the tumor mass remaining after treatment with the relaxin-expressing adenovirus Ad-Δ E1B-RLX was necrotic as shown by hematoxylin -eosin staining, whereas necrotic lesions were detected only Fig. 4 . Relaxin-expressing adenovirus Ad-Δ E1B-RLX and the growth of established tumors and survival of mice. U343, U87MG, C33A, Hep3B, or A549 tumors that were growing subcutaneously in the abdomen of nude mice were injected intratumorally with phosphate-buffered saline (PBS), control adenovirus Ad-Δ E1B, or relaxin-expressing adenovirus Ad-Δ E1B-RLX. A ) Tumor volume was monitored regularly after treatment. Arrows indicate when treatment was given (1 × 10 10 viral particles per 50 μ L for C33A and 5 × 10 10 viral particles per 50 μ L for U343, U87MG, Hep3B, and A549 per treatment). Data are the means and 95% confi dence intervals (CIs) (n = 8 animals per group with U343, C33A, Hep3B, or A549 tumors and n = 9 for U87MG tumors). B ) Overall survival rate. The percentage of surviving mice was determined by monitoring the death of mice over a period of 80 days after treatment. For mice bearing U343 tumors that were treated with PBS, survival probability was 0% (95% CI = 0% to 36.9%); for mice treated with Ad-Δ E1B, survival was 62.5% (95% CI = 24.5% to 91.5%); and for mice treated with Ad-Δ E1B-RLX, survival was 87.5% (95% CI = 47.3% to 99.7%). For mice bearing U87MG tumors that were treated with PBS, survival probability was 0% (95% CI = 0% to 33.6%); for mice treated with Ad-Δ E1B, survival was 44.4% (95% CI = 13.7% to 78.8%); and for mice treated with Ad-Δ E1B-RLX, survival was 88.9% (95% CI = 51.8% to 99.7%). For mice bearing C33A tumors treated with PBS, survival probability was 0% (95% CI = 0% to 36.9%); for mice treated with Ad-Δ E1B, survival was 50% (95% CI = 15.7% to 84.3%); and for mice treated with Ad-Δ E1B-RLX, survival was 100% (95% CI = 63.1% to 100%). For mice bearing Hep3B tumors treated with PBS, survival probability was 0% (95% CI = 0% to 36.9%); for mice treated with Ad-Δ E1B, survival was 50% (95% CI = 15.7% to 84.3%); and for mice treated with Ad-Δ E1B-RLX, survival was 87.5% (95% CI = 47.3% to 99.7%). For mice bearing A549 tumors treated with PBS, survival probability was 25% (95% CI = 0.3% to 52.7%); for mice treated with Ad-Δ E1B, survival was 62.5% (95% CI = 24.5% to 91.5%); and for mice treated with Ad-Δ E1B-RLX, survival was 100% (95% CI = 63.1% to 100%). Ad-Δ E1B-RLX -treated mice survived statistically signifi cantly longer ( P <.001 for U87MG, P = .002 for U343, P <.001 for C33A, P <.001 for Hep3B, P <.001 for A549) than mice treated with Ad-Δ E1B or PBS. Survival was assessed by the Kaplan -Meier method, and the results were compared with a logrank test (SPSS software). All statistical tests were two-sided.
Downloaded from https://academic.oup.com/jnci/article-abstract/98/20/1482/2521847 by guest on 16 February 2019 in the central region of tumors treated with the control adenovirus Ad-Δ E1B ( Fig. 5 , A) . Necrotic lesions in the tumors treated with Ad-Δ E1B-RLX were found mainly on the periphery of the tumor section but not at the center of tumor, where the blood supply is low or nonexistent. These observations indicate that necrosis was most likely the result of injected virus. We also found more adenoviral particles in wider areas of Ad-Δ E1B-RLX -treated tumors, most frequently in the peripheral tumor area, than in Ad-Δ E1B -treated tumors. Furthermore, the level of apoptosis (as determined by the percentage of TUNELpositive cells) was higher in Ad-Δ E1B-RLX -treated tumor tissue (40.2%, 95% CI = 31.1% to 49.2%; P = .023) than in PBS-or Ad-Δ E1B -treated tumor tissue (0.7%, 95% CI = 0% to 1.5%, and 8.1%, 95% CI = 1.6% to 14.7%, respectively). Apoptotic cells were also found mainly in the periphery of the tumor, corresponding to the area of necrosis and adenovirus particles detected. Thus, relaxin appeared to be able to induce apoptosis in vivo as well as in vitro.
Relaxin-Expressing Oncolytic Adenovirus and Collagen Content in Tumors
Sections from xenograft tumors in nude mice treated with PBS, Ad-Δ E1B, or Ad-Δ E1B-RLX were stained with Biebrich's scarlet acid fuchsin (Masson's trichrome stain). Control tumors treated with PBS or Ad-Δ E1B had a high content of collagen, but tumors treated with relaxin-expressing Ad-Δ E1B-RLX appeared to lack collagen, indicating that relaxin expression was associated with a reduction in the expression of collagen ( Fig. 5 , B) . Tumors treated with Ad-Δ E1B-RLX were encapsulated with connective tissue, with collagen found only in the boundary area between tumor and normal tissue. This result closely parallels and supports the fi nding of increased viral spread in the tumor mass and enhanced antitumor effect of a relaxin-expressing oncolytic adenovirus.
Inhibition of Tumor Metastasis by Relaxin-Expressing Oncolytic Adenovirus
Because relaxin-induced matrix metalloproteinase expression has the potential to increase tumor cell metastasis, we evaluated the effect of relaxin-expressing oncolytic adenovirus on tumor metastasis by use of the B16BL6 spontaneous tumor metastasis model. The volume of B16BL6 lung metastases was statistically signifi cantly reduced from that in PBS-treated mice (268 mg) by treatment with Ad-Δ E1B (48 mg; difference = 220 mg, 95% CI = 56 to 387 mg; P = .009) or Ad-Δ E1B-RLX (10 mg; difference = 258 mg, 95% CI = 94 to 426 mg; P = .003) ( Fig. 6 , A) . The average relative tumor burden in the lung from mice treated with Ad-Δ E1B was reduced by 82% and that from mice treated with Ad-Δ E1B-RLX was reduced 96%. Moreover, in three of fi ve mice treated with either Ad-Δ E1B or Ad-Δ E1B-RLX, the formation of metastatic lesions was completely inhibited. Thus, in this model system, the intratumoral injection of relaxin-expressing oncolytic adenovirus into the primary tumor site appeared to reduce, not promote, the formation of metastatic lesions in the lung.
Therapeutic Effi cacy of Systemic Treatment With Relaxin-Expressing Oncolytic Adenovirus
To evaluate the effect of systemically delivered relaxinexpressing oncolytic adenovirus on tumor growth, we used the Hep1 orthotopic hepatoma model. Systemic treatment of mice bearing Hep1 tumors with control Ad-Δ E1B (1.8 mg of tumor per mouse; difference = 18.4 mg, 95% CI = 0.5 to 36.7 mg; P = .007) or relaxin-expressing Ad-Δ E1B-RLX (0 mg; difference = 20.2 mg, 95% CI = 3.7 to 36.7 mg; P = .004) resulted in a marked inhibition of tumor growth compared with PBS-treated controls (20.2 mg) ( Fig. 6 , B) . In fact, only one of four mice in the Ad-Δ E1B group had any liver tumor, and none of the six animals in the Ad-Δ E1B-RLX -treated group had any visible macroscopic tumor lesions. Therefore, systemically delivered relaxinexpressing Ad-Δ E1B-RLX adenovirus appears to inhibit hepatic tumor growth.
Relaxin-Expressing Oncolytic Adenovirus and Toxicity
In preliminary analyses, we assessed potential side effects of relaxin-expressing adenoviruses by monitoring the level of liver transaminases in blood and animal body weights. Intravenous injection of 2 × 10 10 adenoviral particles resulted in moderate increase in AST and ALT levels in one of three mice treated with dl-lacZ or Ad-Δ ElB and modest increase in T-bilirubin levels in one, two, and one of three mice treated with dl-lacZ, dl-lacZ-RLX, and Ad-Δ ElB-RLX, respectively ( Table 2 ) . Moreover, adenoviruses injected intratumorally at the same dose did not increase the level of AST, ALT, or T-bilirubin (data not shown). Furthermore, no specifi c abnormality in general appearance and microscopic examination was observed. These results indicate that relaxin-expressing adenoviruses do not cause evident toxicity. Low-level periportal -sinusoidal lymphocytic accumulation was observed histologically in the livers of mice treated systemically with any one of the four adenoviruses tested ( Fig. 6 , C) . No substantial weight loss was observed in any mice in response to any adenovirus challenge. Thus, neither relaxin-expressing adenoviruses, dl-lacZ-RLX or Ad-Δ ElB-RLX, administered by intravenous (i.e., systemic) or intratumoral injection caused evident Fig. 6 . Therapeutic effi cacy of relaxin-expressing adenovirus Ad-Δ E1B-RLX on spontaneous pulmonary metastasis and orthotopic hepatoma model. A ) Ad-Δ E1B-RLX and spontaneous lung metastasis. B16BL6 tumor-bearing mice were treated with phosphate-buffered saline (PBS), Ad-Δ E1B, or Ad-Δ E1B-RLX three times every other day, and then the primary tumors were surgically removed. Twenty-fi ve days later, the total weight of pulmonary metastatic lesions from each mouse was determined. Each point represents the tumor burden for one mouse (fi ve mice per group), and the mean weight of metastatic lesions for each group, compared with that of PBS treatment (268 mg), is shown with a line (for Ad-Δ E1B, 48 mg, 95% confi dence interval [CI] = 0 to 161 mg, P = .009 versus PBS; for Ad-Δ E1B-RLX, 10 mg, 95% CI = 0 to 27.55 mg, P = .003 versus PBS; and for Ad-Δ E1B-RLX versus Ad-Δ E1B, P = .408). B ) Ad-Δ E1B-RLX and orthotopic hepatic tumor growth by systemic administration. Seven days after the implantation of 1 × 10 5 Hep1 human hepatic cancer cells into the liver, mice were randomly assigned to treatment with PBS (n = 5 mice), Ad-Δ E1B (n = 4 mice), or Ad-Δ E1B-RLX (n = 6 mice) three times every other day by tail-vein injection. Livers were then isolated 42 days after Hep1-cell implant. Each point represents the tumor burden for one mouse, and the mean weight of tumor lesions for each group is shown with a line . P = .004 for Ad-Δ E1B-RLX versus PBS. C ) Histologic analysis of liver tissue from mice treated with adenovirus dl-lacZ, dllacZ-RLX, Ad-Δ ElB, or Ad-Δ ElB-RLX intravenously (each with 2 × 10 10 viral particles in 100 μ L). Hematoxylin -eosin staining. Scale bar is100 μ m. 
* Each of the three mice (m1, m2, and m3) weighed 20 -21 g. PBS = phosphate-buffered saline; AST = aspartate aminotransferase; ALT = alanine aminotransferase; NT = not tested; − = normal; + = abnormal liver function. The microscopic examinations for all organs were normal. The general appearance for all mice tested was normal.
To elucidate how relaxin increased the potency of adenoviruses, we fi rst investigated the induction of apoptosis by use of TUNEL and FACS analyses. Relaxin-expressing adenoviruses induced more tumor cells to become apoptotic than non -relaxinexpressing control adenoviruses. Relaxin expression mediated by other adenoviruses, such as green fl uorescent protein -expressing replication-incompetent adenovirus (dl-GFP-RLX) and human telomerase reverse transcriptase (TERT) promoter -controlled replication-competent adenovirus (Ad-TERT-Δ 19-RLX), also increased the number of apoptotic cells (data not shown). Furthermore, plasmid-mediated relaxin expression also increased the size of the sub-G 1 population in cultures of U343 and A549 cells, indicating that relaxin may have a direct role in inducing apoptosis (Supplementary Fig. 2 ) .
A limitation of this study is that the mechanism by which relaxin induces apoptosis is not clearly understood. Relaxin activates the mitogen-activated protein kinase pathway ( 18 ) and causes the release of nitric oxide ( 19 ) , both of which could play a role. The receptors for relaxin, LGR7 and LGR8, have also been identifi ed ( 20 , 21 ) . LGR7 and LGR8 are heterotrimeric G-protein -coupled receptors that mediate the action of relaxin through the cyclic adenosine 3 ′ ,5 ′ -monophosphate -dependent pathway. The possibility cannot be ruled out that the extracellular matrix -degradative and -remodeling functions of relaxin also play a role in the induction of apoptosis by changing the number and availability of receptors, as well as rearranging cytoskeletal elements in the cell and thus triggering apoptosis. Alternatively, induction of apoptosis by relaxin and/or E1A gene product of replicating adenovirus could also accelerate viral spread. Apoptotic bodies typically contain organelles and/or nuclear DNA fragments, and these bodies can play a role in dispersing adenovirus throughout the intercellular spaces when apoptotic cells are rapidly phagocytosed by neighboring cells ( 22 ) . Support that induced apoptosis increases viral spread is provided by our previous reports ( 12 , 16 ) that adenoviruses, in which the E1B 19-kDa gene is deleted, potently enhanced apoptosis, increased cytolytic potency, and accelerated plaque development. The relaxin-expressing adenovirus that we used is an E1B 19-kDa and E1B 55-kDa double-deleted replicating adenovirus-expressing relaxin that thus induces relaxin-and E1A-mediated apoptosis and direct viral cytolysis, all of which ultimately appeared to lead to an increased antitumor effect.
Relaxin has been shown to induce the expression of matrix metalloproteinases, which may increase the metastatic potential. To investigate the effect of relaxin expression on metastases, we used the B16BL6 mouse melanoma model. Intratumoral administration of Ad-Δ E1B-RLX inhibited the formation of pulmonary metastases of B16BL6 melanoma cells in mice. We cannot rule out the possibility that the observed reduction in metastatic potential was also a result of a direct inhibitory effect of the relaxin-expressing oncolytic adenovirus on the growth of the primary tumor rather than on the metastatic potential. The effect of relaxin on metastasis should be further and rigorously investigated with other metastatic models. Furthermore, systemic delivery of relaxin-expressing oncolytic adenovirus also completely inhibited the growth of orthotopically implanted Hep1 hepatocellular carcinomas. Thus, relaxin-expressing oncolytic adenovirus appeared to elicit a potent antitumor effect against solid tumors and metastatic tumors when injected locally or systemically. Moreover, we would expect the therapeutic advantage of treatment with relaxin-expressing oncolytic adenovirus that we demonstrated in a murine model of spontaneous metastasis to be toxicity, compared with their corresponding control adenoviruses, dl-lacZ and Ad-Δ ElB.
D ISCUSSION
The pressing challenge for contemporary gene therapy is to deliver an effective level of therapeutic genes to cancer cells throughout a tumor in vivo. The extracellular matrix provides one barrier to adenoviral dispersion in a tumor. To overcome this barrier, we inserted the gene for relaxin, an enzyme that degrades the extracellular matrix, into adenoviruses. By using these relaxinexpressing adenoviruses, we have demonstrated that relaxin expression increased the dispersion of the virus from cell to cell within the tumor and the induction of tumor cell apoptosis. Thus, the expression of relaxin by replicating adenoviruses increased the antitumor activity of these adenoviruses in all fi ve tumor xenograft models examined, including the inhibition of tumor growth and metastases. This study is, to our knowledge, the fi rst to report that the use of relaxin achieved a therapeutic benefi t with increased distribution of viral vectors in tumor tissues. We have also demonstrated the ability of relaxin expression by replicationincompetent adenoviruses to increase transduction effi ciency and by oncolytic adenoviruses to increase the survival of mice.
An important issue in replicating virus-based cancer gene therapy that has received little attention is the limited distribution that such viruses have been able to achieve in solid tumors ( 17 ) . To infect cells that are located far from the site of viral inoculation, replication-competent adenovirus must transverse the extracellular space and connective tissue between many cells to reach such uninfected cells. To increase the distribution of replicating virus within tumors, we explored the use of relaxin, an enzyme that degrades the cell matrix, to increase viral spread and tumor tissue penetration. We found that relaxin-expressing adenoviruses (dl-lacZ-RLX) penetrated into the core of spheroids composed of tumor cells but that adenoviruses that did not express relaxin (dl-lacZ) were restricted to a few outer layers of cells. This same effect was observed in xenograft tumors in mice. Moreover, the enhanced effi ciency of gene transfer and viral spread by use of dl-lacZ-RLX and dl-GFP-RLX was also evident in primary human tumors from patients with breast cancer or patients with colon cancer (Supplementary Fig. 1 , B and Supplementary Fig. 3 ; available at: http://jncicancerspectrum.oxford journals.org/jnci/content/vol98/issue20 ). Thus, relaxin expression increased viral spread and tumor tissue penetration both in vitro and in vivo.
The mechanism by which relaxin increases the ability of adenoviruses to infect tumors or spheroids appears to be related to its degradation of the extracellular matrix. We observed that the gene transfer effi ciency of relaxin-expressing adenoviruses was greater than that of non -relaxin-expressing adenoviruses. Because tumor spheroids were cultured with viruses for 3 days, residual relaxin-expressing adenoviruses had enough time to infect cells progressively closer to the core of the spheroid. In vivo, repeated treatments of established xenografts with adenoviruses provided enough time for relaxin to reduce the amount of extracellular matrix in tumor tissue to allow the penetration and spread of adenoviruses into the tumor. In both tumors and spheroids, previous exposure to relaxin-expressing replication-incompetent dl-lacZ-RLX adenoviruses appeared to make the tumor environment more favorable to subsequent viral infections. enhanced in humans because human tumor cells are more permissive to adenoviral infection and replication than murine cells.
The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo. The use of relaxin expression from replicating adenoviruses increased the ability of adenovirus to disperse from one cell to another cell and increased the induction of apoptosis in all fi ve tumor xenograft models examined. Thus, the expression of relaxin may increase the effi cacy of virus-mediated cancer gene therapy.
